Skip to main content
Equibles

Avidity Partners Management LP

Position in GMAB — Genmab A/S

CIK 1791827 DALLAS, TX
Back to GMAB Full portfolio

Position in GMAB

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$1,373,500
+$32,000 QoQ
Shares Held
50,000
0.0% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
#82
of 292 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in GMAB Over Time

Shares Held

Position Value (USD)

Derivatives in GMAB

reported options exposure · as of Mar 31, 2025
CallValue
$8,480,098
CallShares
433,100
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Avidity Partners Management LP holds $524,784,316 across 27 Biotechnology names. GMAB ranks #19 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 DNTH
Dianthus Therapeutics, Inc. /DE/
 2,104,184 $205,115,856
2 CGON
CG Oncology, Inc.
 1,398,948 $99,395,255
3 ORKA
Oruka Therapeutics, Inc.
 760,424 $72,369,552
4 JBIO
Jade Biosciences, Inc.
 1,700,708 $37,789,731
5 ELVN
Enliven Therapeutics, Inc.
 550,000 $27,912,500
6 AKTS
Aktis Oncology, Inc.
 484,200 $15,605,766
7 PVLA
Palvella Therapeutics, Inc.
 70,000 $10,697,400
8 IMUX
Immunic, Inc.
 669,941 $10,296,993

All Filings in GMAB

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,373,500 50,000
2026-03-31 $1,341,500 50,000
2025-12-31 $2,833,600 92,000
2025-09-30 $7,609,227 248,100
2025-06-30 $13,429,000 650,000
2025-03-31 $8,480,098 433,100